Pharmaceutical company AcuCort has published its newsletter for May 2026. In the newsletter, the company highlights key milestones, including the launch and sales in the Nordic market, the commercial agreement with Glenmark Pharmaceuticals, and the ongoing work towards a future market approval application in the United States.
The newsletter also includes recorded presentations, including the Q1 presentation.
The newsletter is available here:
https://bit.ly/4uyczVu
Would you like to receive future newsletters directly in your inbox?
Sign up here:
https://www.acucort.se/EN/media/subscribe/
For further information:
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.